These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.
first published: May 24, 2016 10:11 am
A collection of the most-viewed Moneycontrol videos.
This Tenant Moved from a 100sqft Slum to a Premium Residence | The Tenant
Live: Nifty snaps 4-day winning streak but rises 1% this week | Closing Bell
Live: Can Bihar poll outcome trigger Nifty to reclaim 26,000-mark? | Opening Bell
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
